BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA. BYETTA has been available in the U.S. since June 2005 and is used in more than 60 countries worldwide to improve ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

New PDUFA Action Date Expected Within 14 Days, per FDA Guidelines SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: ...

BYDUREON and BYETTA both contain the same active ingredient, exenatide, and therefore should not be used together. BYDUREON is not insulin and should not be taken instead of insulin. BYDUREON is not ...

WASHINGTON (Reuters) - Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the ...

SAN DIEGO — Use of a drug for Type 2 diabetes made by Eli Lilly and Amylin Pharmaceuticals may lower patients’ risk of heart failure, according to a new study. The study of more than 778,000 patients ...

in a partnership which was dissolved last year. The drug had been rejected twice before, which caused AMLN to lose nearly half of its market value in October 2010. Bydureon is expected to be available ...

SAN DIEGO Amylin Pharmaceuticals is pushing ahead in its effort to win approval for a long-acting Type 2 diabetes drug, according to a first-quarter earnings statement by the drug maker. Amylin said ...

Both natural supplements above are alternatives to Byetta (Exenatide). Both can be used in combination (or stacked) for greater benefit. Both products are made by two different manufacturers and so ...

Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta. The drugmakers asked the FDA ...